Drug for spinal injury repairs DNA in Alzheimer brains

Most Alzheimer’s drugs aim at a single target, usually the amyloid or tau protein. KCL-286 takes a different approach. The study shows the compound addresses multiple disease pathways at once, which in theory gives it an advantage over the current generation of treatments.

DNA damage: an overlooked driver

Ageing brain cells accumulate DNA damage over time. This has long been recognised as a feature of Alzheimer’s disease, but it has rarely been a direct treatment target. KCL-286 appears to intervene in this mechanism. In mouse models, it repaired measurable DNA damage and reduced neuroinflammation (chronic inflammation in the nervous system) simultaneously, a process that otherwise accelerates neuronal loss.

The compound also affected several disease-related pathways at once, without focusing exclusively on amyloid or tau. That is notable: the large majority of Alzheimer’s drugs that have failed in recent decades targeted a single molecule.

Human safety data already exists

KCL-286 has already completed a phase-1 human safety trial for its original spinal cord injury indication. That matters: researchers do not need to restart safety testing from scratch, which could accelerate the path toward a clinical Alzheimer’s trial.

Mouse studies rarely translate directly to humans, however. The effects reported here are preliminary and encouraging, but they have not yet been demonstrated in patients. Larger, controlled clinical trials are needed to determine whether the drug works in people with Alzheimer’s disease.

From a longevity standpoint, DNA repair in ageing neurons is a particularly relevant mechanism. DNA damage is one of the fundamental hallmarks of cellular ageing, well-documented far beyond Alzheimer’s disease alone.

Read the original article